Treatment with Herceptin (trastuzumab) and Perjeta (pertuzumab) with endocrine therapy but without chemotherapy has been shown to potentially be an effective treatment for patients with HER2-positive ...

Treatment with Perjeta (pertuzumab), Herceptin (trastuzumab) and chemotherapy (Perjeta-based regimen) for one year as post-surgery treatment showed a statistically significant overall survival (OS) ...

Roche's Perjeta, Herceptin and chemotherapy regimen cut the risk of death by 17% in patients with early-stage HER2-positive breast cancer over 10 years.

Using Medicare claims, we documented US prescribing patterns for originator biologic trastuzumab (Herceptin), a targeted cancer therapy, and five biosimilar entrants since 2019. The first ...

After ten years, the risk of death was reduced by 17% for people treated with Perjeta ® (pertuzumab), Herceptin ® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for a year as post ...

The Food and Drug Administration (FDA) has approved Hercessi ™ (trastuzumab-strf), a biosimilar to Herceptin ® (trastuzumab). Hercessi, a a HER2/neu receptor antagonist, is indicated for ...

Preclinical data presented at the 95th annual meeting of the American Association of Cancer Research (AACR) demonstrate that INGN 241 enhances the anti-tumour effects of Herceptin (Trastuzumab) in ...

The FDA has approved trastuzumab-strf as a biosimilar to trastuzumab for the treatment of certain patients with HER2-overexpressing malignancies, according to a press release from the agent&rsquo ...

The cost of the first biosimilar was $13,621 lower than the originator in 2019. Currently, the mean unweighted biosimilar treatment cost is 40% lower than Herceptin, at $38,173.

Shanghai Henlius Biotech’s partner, Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, has received permission from the Food and Drug Administration for Hercessi (HLX02 ...

Herceptin’s average sales price (ASP) declined 21% between second-quarter 2019 and second-quarter 2022. The five biosimilar entrants not only entered with lower price points, but within three years, ...